Back to results
US 10,092,589 B2Granted
Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorHiroyuki Okabe
Life of this patent
Estimating the term…
Abstract
In order to provide a novel cancer treatment method using a FTD⋅TPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTD⋅TPI combination drug and an anti-tumor platinum complex are administered in combination.
Claims8
A method for treating a tumor in a mammal comprising:
- administering an anti-tumor platinum complex and a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, in combination to the mammal,
- wherein a daily dose of the combination drug on an administration day of the combination drug is 50 to 100% of a recommended dose of the combination drug for use in monotherapy, and a daily dose of the anti-tumor platinum complex on an administration day of the anti-tumor platinum complex is 50 to 100% of a recommended dose of the anti-tumor platinum complex for use in monotherapy,
- wherein the anti-tumor platinum complex is cisplatin, carboplatin, or oxaliplatin.
A method selected from the group consisting of:
- a method of enhancing an anti-tumor effect of an anti-tumor platinum complex, the method comprising:
- administering an anti-tumor agent consisting of a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 to a mammal;
- a method of enhancing an anti-tumor effect of a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, the method comprising:
- administering an anti-tumor agent consisting of an anti-tumor platinum complex to a mammal;
- a method for treating a cancer patient having received an anti-tumor platinum complex, the method comprising:
- administering an anti-tumor agent consisting of a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 to the cancer patient;
- and
- a method for treating a cancer patient having received a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5, the method comprising:
- administering an anti-tumor agent consisting of an anti-tumor platinum complex to the cancer patient,
- wherein a daily dose of the combination drug on an administration day of the combination drug is 50 to 100% of a recommended dose of the combination drug for use in monotherapy, and a daily dose of the anti-tumor platinum complex on an administration day of the anti-tumor platinum complex is 50 to 100% of a recommended dose of the anti-tumor platinum complex for use in monotherapy,
- wherein the anti-tumor platinum complex is cisplatin, carboplatin, or oxaliplatin.
8 more elements
Dependencies are inferred from the claim text.